REFERENCES
- Hammar SP. Pleural diseases. In: Dail DH, Hammar SP, eds. Pulmonary Pathology, ed 2. New York: Springer-Verlag; 1994:1463–1579.
- Henderson D, Comin CE, Hammar SP, Shilkin KB, Whitaker D. Malignant mesothelioma of the pleura: current surgical pathology. In: Corrin B, ed. Pathology of Lung Tumors. New York: Churchill-Livingstone. 1997:41–80.
- Hammar SP. Pleural neoplasms. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. New York: Churchill-Livingstone. 2002:267–312.
- Hammar SP. Pleural neoplasms. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry, ed 2. In press.
- Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesothelioma. Hum Pathol. 1998;29:1382–1392. [PUBMED], [INFOTRIEVE], [CSA]
- Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA-19-9, HBME-1 and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84:101–108. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Khoor A, Whitsett JA, Stahlman MT, , et al. Utility of surfactant protein B precursor and thyroid transcription factor-1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999;30:695–700. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Curry PM, Butcher DN, Fisher C, , et al. Value of the mesothelium associated antibodies thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107–112. [CSA], [CROSSREF]
- Oates J, Edwards C. HBME-1, MOC-31, WT-1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341–342. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chieng DC, Yee H, Schaefer D, , et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer. 2000;25:194–200. [CSA], [CROSSREF]
- Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma: review and update. Am J Clin Pathol. 1999;112:75–89. [PUBMED], [INFOTRIEVE], [CSA]
- Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol. 2002;33:953–967. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031–1051. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Comin CE, Novelli L, Boddi V, , et al. Calretinin, thrombomodulin, CEA and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529–536. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang PJ, Genega EM, Tomaszewski JE, , et al. The role of calretinin, inhibin, melan-A, BCL-2 and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591–597. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laskin WB, Miettinen M. Epithelioid sarcoma: new insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med. 2003;127:1161–1168. [PUBMED], [INFOTRIEVE], [CSA]
- Pan C, Chen DC, Choo T, , et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003;34:1155–1162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fine SW, McClain SA, Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol. 2004;122:552–559. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]